AXL expression
|
NSCLC
|
AXL expression
|
NSCLC
|
pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria
|
AXL expression
|
CRC
|
AXL expression
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
AXL expression
|
Melanoma
|
AXL expression
|
Melanoma
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
AXL expression
|
RCC
|
AXL expression
|
RCC
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
AXL expression
|
NSCLC
|
AXL expression
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|